Bristol Myers Squibb is making progress paying down debt from prior deals and improving financial flexibility so it can make ...

Bristol-Myers Squibb Company (NYSE:BMY) is included among the 14 Best Pharma Dividend Stocks to Buy in 2025. The company has dealt with some hurdles in the past, but it has secured several key new ...

Bristol Myers Squibb & Co. (NYSE:BMY) on Friday announced topline results from the Phase 3 INDEPENDENCE trial evaluating ...

An international Phase 2 trial will test BMS-986368 as a potentially new oral therapy for managing multiple sclerosis-related ...

Bristol-Myers Squibb Company (NYSE: BMY) is one of the best cheap stocks under $50 to buy now. In a report released on July ...

Pfizer, Inc. (NYSE:PFE) is one of the high-margin pharma stocks to buy now. Bristol-Myers Squibb Company (NYSE:BMY) and ...

Pfizer and Bristol Myers Squibb have launched a direct-to-patient program offering their blood thinner Eliquis at a 40% discount for cash-paying patients.  The list price for Eliquis (apixaban) is ...

An Omnicom spokesperson confirmed that the 2025 MM+M Agency 100 honoree will soon be folded into Omnicom Health subsidiaries.

Despite a phase 3 flop, Bristol Myers Squibb—encouraged by “clinically meaningful results” and bruised by three other recent pivotal trial failures—still plans to discuss a potential approval filin | ...

Bristol Myers Squibb said on Friday its blockbuster drug Reblozyl in combination with another therapy failed to meet the main ...

Sino Biopharma will acquire LaNova Medicines, which has licensed cancer drugs for Merck and AstraZeneca, for $951 million.

Despite the failure, BMS remains “encouraged” by Reblozyl’s clinical activity in myelofibrosis-associated anemia and will approach regulators to discuss potential submissions for this indication, for ...